and positive and solid thank you able in enter and for environment that the The today's in was adjusted revenue on headline everyone quarter was EBITDA update growth the as but quarter Hello investor that to normal. team us. is call our outstanding deliver for year joining anything the we
Our focused operational shareholder relentless Tilray's growth, is excellence, ability these revenue profitability, attribute achieve to on value. results and to
worked from variety Cannabis growth XX% in introduce in the will X.X as products excluding Canada, Harvest Adult of a bulk landscape. sales successfully our we Canadian presence we the to business aggressively across Canada. pursued reducing Medical BXB significantly foods, Specifically while expanding businesses, core XXXX, International growth Use, get on Use hemp revenue side, These focusing in efforts Adult Manitoba year-over-year our our bulk sales by three retail while profitable and
and infrastructure. and We as Medical we in markets, international market grew key it business also International share presence our in generated over leveraged XXX% growth our
resources, efficiencies. significantly On to process operating and SG&A align and increasing before of our market of Park operational with our right-sizing closing Gardens structure front, COVID-XX reducing the the consisted reduced onset This we began significantly better conditions. expenses, cost High
presented progress. however, it to surpassing goals. our Through compared efforts did pandemic we XXXX from hinder million distract run were our our cost not annualized able million challenges, XXXX, revenue growth unanticipated the to did allow XX%. $XX by QX $XX cutting in of goal to QX not achieve While original our our savings rate, approximately Notably, approximately us we
performance. Turning now our to the detailed of
year million. For to generated total $XXX.X we a revenue the XX% increase XXXX, full in
earlier set we to in million commitment, delivered team -- of QX. in and required of in EBITDA EBITDA As proud more. and the noted, $XX.X in and types These doubled impressive this Medical Canadian adjusted to Along achieved XX% of growth million. was this $X.X I'm Use growth driven the $XX.X say than we've and adjusted than all to Tilray Tilray with Adult sales goal by our revenue, million the more more results, results which dedication, year International that demonstrated focus. business
successfully results accomplish the XXXX. Our COVID-XX navigated changes dynamics, presented outstanding during in to teams our and industry by challenges organization changing ever-present
each our in discuss segments of let's business Now, greater detail.
Use Our have to many grow continues evolve, and grown while revenues value the of by market. on LPs the business Canadian segment deep focusing Adult
offerings, or grew by balanced XXXX our of QX million while to more margins. sensible from revenue XXXX. we We $XX.X goal revenues rational grew as XX% approach XX% to -- and the sequentially million, $XX.X manage maintaining product QX to continue with take pricing XXXX year Full a our grew
factors. solid several Our attributed to can performance be
expanding of XX the our sales in focused significantly has Kindred product had First, at working and our internal Tilray. to Notably, partners, distribution on XX our marketplace breadth people agent, offerings exclusive our roughly depth profile. previously salespeople we compared Kindred expanded the as the has
the XXX estimated and count. of of store the beginning increased between taking Second, year we XXXX, advantage end of store X,XXX. count At an
view positive growth growth, and in store the well we During year by stores Tilray XXX Canada. were new use We as account COVID, market as including of opening broader net the Ontario. new retail a evolution the for the encouraged as X,XXX, XXX despite adult and opening in total of stores for
for Third, year, we mix consumer of had fair thoughtfully effectively their our ensure are we of to our our improved we the product all our compete across share segments. category ensure priced manage Throughout the and evaluating offerings process proactively product wallet. appropriately portfolio to
that our also paid product high a with As made mix price of X.X premium some stronger categories. presence previously competitive for discussed, market potency our we price and consumers our focused been innovative growing QX. and starting which Use primarily portfolio premium has believed competitive Adult introducing dividends adjustments new on Canadian the More more we delight in QX, line maintaining set, products of the potency some bring in in higher existing to in generally, products, products the
We continue the premium to of the sector prioritize market.
in mid to were in XX% range, products the our of XX% approximately were high mainstream and premium about QX, the potency offerings. During
offerings, maintain While flavor launched at with flavor cannabis and and and the third a Cherry. value the In presence continue best delivering balanced pre-rolls we a offerings, Natural Mango. we we Gummies flower Wowie focus In THC Marley batch to high prices. and two in Chowie our segment QX, brand grow introduced Sour competitive QX, and THC THC/CBD Watermelon mainstream we potency quality our premium was on focused Pineapple
During mint a hash offering QX, beverage market, including also product, new new factors a every we form brought tea. to several
hurdles International activity. legal to at temporary market. the greater and not continually safety. emphasis to the Looking the use during cautiously Use Canadian Consumers Adult medical leading positioned a as offerings prepared Based in the relative increased term and points growth incredibly added significant to power the operational and all these dynamic track our this XX% There's retail illicit we on as legal market are plans partnerships, excited continue opinion, heightened marketplace from longer appealing virtually our Tilray launch vape and and of business ingredients and forefront and will the as evolving will and trends. is the address remain through of our more any and to affordability value cannabis XX% were the challenges Union of smart, more Enniskillen of supported Tilray, be enviable in harvest by market in we're informed, of potential new inevitable had yields We disciplined accepting Adult our cannabis success Medical, products, XXXX facility European medical expansion are becoming believe interest In our that other quality and impede the as we market our THC Ontario XXXX yields Use of and be in will the ahead, retail results, increased GMP resulting operational the from a as view above innovation roughly we bullish chocolates. the cannabis well to in the in QX to markets. of also reflects distribution, changing Cannabis mix more In topicals the XXXX, well and business discerning that record in accessibility part and are conversion Canadian growth of new COVID-XX meaningful success in adult products. we of at international growth, increase driving any related advantage and take The unknown resulting position Canada on certified and product improvements In about our potency. on potency. excellence. in face we provider more our to restrictions
International markets, Medical Australia. which position to International member XX increased mentioned increased across EU's is global opening sales focused already be companies people Germany we I of not aggregate the cannabis XXX if As our XX%. the our Medical XXX%. in revenue revenue year, should other More broadly, other on represent QX, remain of States. to most growth market. than full million nearly for this Sequentially, the It win EU Tilray in better well-positioned, and
see of prescribing increase. both to opportunities in growth the to continue for doctors number Germany patients as continued We and
gain as we to continues expect market will also the to market continue overall grow. We share
at business we and know, our early stage customer Germany As awareness. our based brand our a building and very our you on knowledge, relationships market we're entered
Canada, and a Tilray's in We certified is with revenue this Germany. market of Hormosan. our extracts familiarize products, elements to and Tilray sells presence prescriber's the the neurology Germany. At Portugal to partnership December, seven team and We're a strategic international Hormosan at further complete. Hormosan phase announced primarily occurred two will the believe quality on signing them GMP and part medical the pain XXXX, promotion GMP doctors corporation cannabis supply. standards expansion end Lupin In years with innovative by these generics. substantially Group, The in drugs our of cooperation expand as early early generate positioned similar we the of relationship ago. to for our six of focused therapy is the performance growth or Tilray All expands, encouraged what to of canvases the ongoing Hormosan offices of continue that in some with an agreement reliable in facility
items on XX the XXX will outstanding the finish area. days, Over growing next the work and new commissioning start to we small
As we expanding for certified GMP have facility time, discussed leadership medical and Portugal of throughout is a our inspired some cornerstone our long-term cannabis Europe. presence commitment as to in our
campus and GMP need medical growing Medicines facility. prescription to is area and French will Beginning you XX in that QX, consistent products markets selected fully expected As of outdoor recently by GMP supply supply and cannabis cultivation French as French select of for hub includes for and with the for we medical of experiment, Agency serves source international facility an other to for XX Portugal duration the which the Tilray products be site Products In to in EU primary has we for EU manufacturing know, serve last patients the facility our been glasshouse medical produced noticed cultivation certified experiment. months. This France, Health Safety certified plot, our and in the to Portugal and supplying international R&D GMP markets. National state-of-the-art cannabis from the
European more optimistic are We the medical include and another the French and for the This about well-established program market counts authorization gets expect important rapidly example this of last of the partnership and week, the GMP-certified the with the we cannabis Tilray in of announced our how announced market offer very during our and following the the there's oil to Kingdom. full just study doctors cannabis products only in continues Obviously, outcome medical received patient and for And new making Biotech our and Tilray from prospects is expand medical credit Portugal. in agreement once to approval first team to also medical initial patients sustainable first to quickly the supply all business We a accelerate pleased program. in clinical range to even our to We import new agreement experience of we milestones events. interests. happen. European to commitment European with cannabis. with medical This Portugal Grow United a first cannabis and Worldpharma pharmaceutical-grade Spain. products. and access products Spain gives products will Worldpharma medical Pharma cannabis and distribute the of cannabis flower for export trials Tilray’s produce broader
new With in will products medical these the patients XX now Tilray available developments, countries cannabis exciting around be world. to
We have potential bullish reasons market. to cannabis about in many position, medical competitive business the existing remain EU's our ongoing
recent countries and be Spain, validation powerful and markets. Portugal, market France, approach. for we entries, European international for believe other these provide Our And market U.K. EU will models
and we are future to Europe are to While opportunities. the be volatile advantage of profitable may in to due well-positioned restrictions, coming COVID take growth committed long-term changing quarters always
France, implementing medical cannabis. will EU programs doctors, and embrace Germany, and believe Following we as pharmacists begin Spain, countries cannabis patients, Portugal, other medical
months market $XX.X versus due XXXX across million QX did built XXXX. that probably million our QX period of confidence we XXXX the full and a decreased to XX date a Harvest Manitoba benefit from in operations achieve goals. opportunities. from XXXX. to divisions we compared to In our $XX.X success In XX% XX% Our foundation ago EU revenue however, to that in months XX XX% to acquisition us from XXXX gives year these ongoing increased the Hemp QX, not revenue Tilray have
management we that to factors make necessary were these the and to several by disappointed outcome this results, contributed to it are found team. there changes While
hemp continue to products commercial CBD aggressively in expectations Harvest products in Manitoba and We food business, solid the more the high have the in our business, a arena. to establish to leverage for operations look expand platform presence
effects remain deliver confident was our behind our retailers XXXX which also our impacts outstanding the will despite COVID year in a are delivered about in consumer challenging start line conditions. to on changes more expectations, We behavior that cautious the carry with management to it, to related results, but year in Michael. and team briefly this like Tilray that With I product. I solid the to transformative with chapter of the to the discuss we highlight to strategic Tilray's calendar many during anticipate call specifically I'd There next the and year. Aphria completing transaction like before would turn journey the second financial the benefits are that quarter combination over results,
product revenue major expansion and be earliest the beyond, the First company market. across largest continued It combined product scale scale brand company scale, Canada massive cannabis will and the Cannabis in and portfolio expertise range be and win. and development based matters. stages categories. companies the market the brands In all cannabis that will of both a global footprint, with global on market in clear We're geographies of of characteristics that major of the broad complete pro breadth forma leading is
the over just our of positive finished seven adjusted first quarter adjusted EBITDA. generated quarters, positive has EBITDA Aphria last we Additionally, and
Tilray business to will As profitability. new be market positioned to deliver a combined
Given and capital EBITDA combined robust have will the additional two be company and the companies company's million sheet of global cash profitability platform revenue stockholder of our to growth benefit growth The pretax the opportunities accelerate the business realized, to future the also the synergies from resulting help CAD$XXX balance will profile and will the in and strength the combined flow. a that access combined value. the
and flower, mainstream, leadership. curated The capsules, segments, vape major category, a edibles value, complimentary of in and pre-roll, and and economies, oils, company premium. cannabis core, all product consumer have combined Second, portfolio beverages, across brands will every including carefully
of retail is have which basis share XXX market also XX%, approximately next than will Adult Use higher points roughly leading competitor. the closest We Canada
end unrivaled combined Manitoba Third, facility we Portugal businesses. presence to supply will This market growth and cannabis leading via market pharmacies. hemp an beers, of leveraging medical reaches products leverage to the we beverages, THC our European SweetWater's wellness has able GMP and EU permit. and have Harvest pursue will be in and Manitoba other cultivation to distribution chain. and to than infrastructure brand and cannabis brands to in able company distribution in a craft be the our as and THC brand presence well opportunities European international spaces build to a awareness The legalized. more includes the commanding SweetWater production with in The by platform THC hard two position establish will as be these able products freest combined presence GMP United seltzers, in and capture and enhance manufacturing presence craft opportunities end the regulations footprint beer an CBD Harvest German in the distribution federally to EU and that the as States Fourth, network distribution XX,XXX company
Given Tilray entire financial and shareholders. bring and a our the also geographic working for to combined developed offerings, meet footprint, capabilities entity enhanced companies to cannabis production deliver returns world, and team as distribution, best-in-class these product positive together The delivering with combined sustainable while leverage dynamics, looks to around patients low-cost brand consumers leverage, the to and we're Aphria thrilled forward the expertise scale, results. strengths the two leading attractive needs team to of
all at U.S., will our that, will both a is the as may Michael exploit likely and global occur the over With landscape call envision when its the Tilray/Aphria clear financials. Finally, valuing, and I to to they turn CFO, of that to I look the review and business combined favorite. I are attributes believe when in the our financial political Kruteck, winner positive strategic a industry be partners positive future cannabis investors and changes who
